MetaCap

Solventum Corporation (SOLV)

NYSE: SOLVHealth CareMedical/Dental InstrumentsUSD

84.50-1.30 (-1.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SOLV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.36B
52-week range
62.38 – 94.16
Day range
84.13 – 87.11
Volume / Avg
658.35K / 1.03M
Beta
—

52-week range

$62.38$94.16

SOLV stock today

Shares of Solventum (SOLV) finished lower on Nov 20 at $84.50, a drop of 1.52% or $1.30 per share, versus the S&P 500's 3.70% decline. At this level, SOLV sits in the middle of its 52-week range of $62.38 to $94.16: 10.3% below the high, set on Sep 1, 2026 and 35.5% above the low. SOLV is up 6.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.9%.

At 94.9x trailing earnings, Solventum trades above the peer-group median of 42.4x. Its forward P/E of 11.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Solventum

Company profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V.

Industry
Medical/Dental Instruments
CEO
Mr. Bryan C. Hanson
Headquarters
Eagan, MN
Employees
20,584
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Solventum generated $8.32 billion in revenue, up 0.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.56 billion (+224.8% year over year), for a net margin of 18.7% versus a median of 16.4% in the prior 3 years. Gross margin was 53.5% (down from 55.6%) and operating margin 26.2%.

Solventum annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$8.32B$8.25B$8.20B$8.13B
Growth+0.86%+0.70%+0.82%—
Net income$1.56B$479.00M$1.35B$1.34B
EPS (diluted)$8.88$2.76$7.79$7.78

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$98.38+16.43%

  • Strong buy 1
  • Buy 7
  • Hold 5
  • Sell 1
  • Strong sell 1

Target range

Low $75.00High $115.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.07 vs $1.35
Surprise
-105.19%

SOLV news

All SOLV news

Solventum peers

Health Care sector
SOLV peer companies
CompanyPrice% ChgMarket capCompare
GKOSGlaukos Corporation237.31-0.33%$14.05Bvs SOLV
BAXBaxter International Inc.25.390.00%$13.14Bvs SOLV
PENPenumbra Inc.319.12-0.28%$12.58Bvs SOLV
PODDInsulet Corporation133.17-2.96%$9.24Bvs SOLV
GMEDGlobus Medical Inc. Class A66.89-2.49%$8.86Bvs SOLV
TFXTeleflex Incorporated161.58-1.11%$6.41Bvs SOLV
HAEHaemonetics Corporation120.16-0.17%$5.47Bvs SOLV
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs SOLV

Indexes, lists and sector

Solventum stock FAQ

What is Solventum's stock price today?

SOLV last traded at $84.50 as of Nov 20, 4:00 PM EST, down 1.52% on the day. Prices are delayed at least 15 minutes.

What is SOLV's P/E ratio?

SOLV trades at a trailing P/E ratio of 94.94 and a forward P/E of 11.20, compared with a median of 42.4 for its closest peers.

Is Solventum in the S&P 500?

Yes. Solventum (SOLV) is a constituent of the S&P 500 index.

Who is Solventum's CEO?

Mr. Bryan C. Hanson is the chief executive officer of Solventum Corporation, which has about 20,584 employees.

What is the SOLV 52-week high?

The 52-week high for SOLV is $94.16 and the 52-week low is $62.38. The stock is currently 10.3% below its high.

Compare SOLV